Regentis Biomaterials Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	7.38	0.23	0.35	1.24	2.74
Cash & Short-Term Investments	7.38	0.23	0.35	1.24	2.74
Cash Growth	3121.83%	-33.62%	-72.18%	-54.81%	98.98%
Other Receivables	0.23	0.07	0.01	0.03	0.05
Receivables	0.23	0.07	0.01	0.03	0.05
Prepaid Expenses	0.01	0.18	0.01	0.45	0.33
Total Current Assets	7.62	0.48	0.36	1.72	3.12
Total Assets	7.62	0.48	0.36	1.72	3.12
Accounts Payable	0.27	0.25	0.35	0.21	0.31
Accrued Expenses	1.41	1.13	0.52	0.42	0.2
Short-Term Debt	1.2	0.57	0.21	-	-
Current Portion of Long-Term Debt	-	4.37	-	6.47	-
Current Unearned Revenue	-	-	2.05	1.98	2.21
Other Current Liabilities	-	0.16	0	0	0
Total Current Liabilities	2.87	6.49	3.14	9.08	2.72
Long-Term Debt	-	-	7.41	-	6.08
Other Long-Term Liabilities	-	-	0.62	0.69	0.79
Total Liabilities	2.87	6.49	11.17	9.77	9.58
Additional Paid-In Capital	60.54	1.04	1.04	0.75	0.75
Retained Earnings	-55.79	-42.15	-46.95	-42.82	-41.23
Total Common Equity	4.74	-41.1	-45.91	-42.06	-40.48
Shareholders' Equity	4.74	-6.01	-10.81	-8.05	-6.47
Total Liabilities & Equity	7.62	0.48	0.36	1.72	3.12
Total Debt	1.2	4.95	7.62	6.47	6.08
Net Cash (Debt)	6.18	-4.72	-7.27	-5.23	-3.33
Net Cash Per Share	10.91	-29.08	-41.90	-32.26	-20.54
Filing Date Shares Outstanding	5.18	0.16	3.93	0.16	0.16
Total Common Shares Outstanding	5.18	0.16	0.16	0.16	0.16
Working Capital	4.74	-6.01	-2.78	-7.36	0.39
Book Value Per Share	0.92	-253.42	-283.02	-259.32	-249.57
Tangible Book Value	4.74	-41.1	-45.91	-42.06	-40.48
Tangible Book Value Per Share	0.92	-253.42	-283.02	-259.32	-249.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q